BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.17
arrow_upward
+0.62%(+0.050) 1D
$8.17
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$8.12
High
$8.20
Low
$7.92
Mkt. cap
2.09B
Avg. vol.
4.69M
Volume
6.15M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
Open
$8.12
High
$8.20
Low
$7.92
Mkt. cap
2.09B
Avg. vol.
4.69M
Volume
6.15M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Yahoo Finance
·
18 minutes ago
4 Stocks Delivered About Half of the S&P 500's Gain This Year
CNBC TV18
·
23 minutes ago
Nasdaq hits new record high, US markets close in green even as US job growth undershoots expectations
Investor's Business Daily
·
2 hours ago
Dow Jones Futures: Nasdaq Hits High As Nvidia, SpaceX, Bloom Energy Flash Buy Signals. What To Do Now.
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com